4D Molecular Therapeutics (NASDAQ: FDMT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.820 | ||||||
REV | 1.219M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of 4D Molecular Therapeutics (NASDAQ: FDMT) through any online brokerage.
Other companies in 4D Molecular Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharmaceuticals (NASDAQ:KALV) and Jounce Therapeutics (NASDAQ:JNCE).
The latest price target for 4D Molecular Therapeutics (NASDAQ: FDMT) was reported by SVB Leerink on Friday, May 13, 2022. The analyst firm set a price target for 28.00 expecting FDMT to rise to within 12 months (a possible 258.51% upside). 2 analyst firms have reported ratings in the last year.
The stock price for 4D Molecular Therapeutics (NASDAQ: FDMT) is $7.81 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for 4D Molecular Therapeutics.
4D Molecular Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for 4D Molecular Therapeutics.
4D Molecular Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.